

Effects of Evening vs Morning Levothyroxine Intake

A Randomized Double-blind Crossover Trial

Nienke Bolk, MD; Theo J. Visser, PhD; Judy Nijman, BSc; Ineke J. Jongste, RN; Jan G. P. Tijssen, PhD; Arie Berghout, MD, PhD, FRCP

Background: Levothyroxine sodium is widely prescribed to treat primary hypothyroidism. There is consensus that levothyroxine should be taken in the morning on an empty stomach. A pilot study showed that levothyroxine intake at bedtime significantly decreased thyrotropin levels and increased free thyroxine and total triiodothyronine levels. To date, no large randomized trial investigating the best time of levothyroxine intake, including quality-of-life evaluation, has been performed.

Methods: To ascertain if levothyroxine intake at bedtime instead of in the morning improves thyroid hormone levels, a randomized double-blind crossover trial was performed between April 1, 2007, and November 30, 2008, among 105 consecutive patients with primary hypothyroidism at Maastad Hospital Rotterdam in the Netherlands. Patients were instructed during 6 months to take 1 capsule in the morning and 1 capsule at bedtime (one containing levothyroxine and the other a placebo), with a switch after 3 months. Primary outcome measures were thyroid hormone levels; secondary outcome measures were creatinine and lipid levels, body mass index, heart rate, and quality of life.

Results: Ninety patients completed the trial and were available for analysis. Compared with morning intake, direct treatment effects when levothyroxine was taken

at bedtime were a decrease in thyrotropin level of 1.25 mIU/L (95% confidence interval [CI], 0.60-1.89 mIU/L; $P < .001$), an increase in free thyroxine level of 0.07 ng/dL (0.02-0.13 ng/dL; $P = .01$), and an increase in total triiodothyronine level of 6.5 ng/dL (0.9-12.1 ng/dL; $P = .02$) (to convert thyrotropin level to micrograms per liter, multiply by 1.0; free thyroxine level to picomoles per liter, multiply by 12.871; and total triiodothyronine level to nanomoles per liter, multiply by 0.0154). Secondary outcomes, including quality-of-life questionnaires (36-Item Short Form Health Survey, Hospital Anxiety and Depression Scale, 20-Item Multidimensional Fatigue Inventory, and a symptoms questionnaire), showed no significant changes between morning vs bedtime intake of levothyroxine.

Conclusions: Levothyroxine taken at bedtime significantly improved thyroid hormone levels. Quality-of-life variables and plasma lipid levels showed no significant changes with bedtime vs morning intake. Clinicians should consider prescribing levothyroxine intake at bedtime.

Trial Registration: isrctn.org Identifier: ISRCTN17436693 (NTR959).

Arch Intern Med. 2010;170(22):1996-2003

Author Affiliations:

Department of Internal Medicine, Maastad Hospital Rotterdam, Rotterdam (Drs Bolk and Berghout and Mss Nijman and Jongste), Department of Endocrinology, Erasmus Medical Center Rotterdam, Rotterdam (Dr Visser), and Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam (Dr Tijssen), the Netherlands.

BECAUSE THE PREVALENCE OF primary hypothyroidism is high among the general population,^{1,2} levothyroxine sodium is one of the most prescribed medications. Absorption of levothyroxine is approximately 70% to 80% and occurs in the small bowel.³ There is consensus that levothyroxine should be taken before breakfast to prevent interference of its intestinal uptake by food or other medications.⁴⁻¹⁰ In our clinics, we observed several patients whose thyroid hormone levels improved markedly after changing the scheduled intake of levothyroxine to bedtime. A pilot study¹¹

confirmed this observation among 11 patients. The mean (SD) plasma thyrotropin level significantly decreased from 5.1 (0.9) to 1.2 (0.3) mIU/L (to convert thyrotropin level to micrograms per liter, multiply by 1.0), and free thyroxine (FT₄) and triiodothyronine (T₃) levels increased when levothyroxine was taken at bedtime. The circadian pattern of thyrotropin rhythm remained intact, which was important regarding the time of blood sampling for thyrotropin levels to monitor levothyroxine therapy.

Accordingly, we conducted a randomized double-blind crossover trial to confirm whether levothyroxine taken at bed-




Figure 1. Flowchart of the study, showing disposition of patients from screening to study completion. Consecutive patients with primary hypothyroidism who visited our clinics were assessed for study eligibility. Study exclusion criteria were gastrointestinal disorder, thyroid carcinoma, and pregnancy.

time leads to lower thyrotropin and higher FT₄ and T₃ levels. Hypothyroidism can have major effects on health and quality of life (QOL), as it is associated with fatigue, weight gain, cold intolerance, depression, neuromuscular symptoms, diastolic dysfunction, and impairment of renal function.¹²⁻¹⁵ It is also associated with risk factors for cardiovascular disease, such as hyperlipidemia, hyperhomocystinemia, and arterial hypertension, notably in the case of insufficient thyroid hormone supplementation.^{16,17}

The primary objective of this study was to determine whether a change occurred in thyrotropin and thyroid hormone levels when levothyroxine was taken at bedtime vs in the morning. We further investigated whether a bedtime regimen would affect creatinine and lipid levels, body mass index, heart rate, and QOL.

METHODS

STUDY PARTICIPANTS

A randomized double-blind crossover trial was performed among consecutive patients with primary hypothyroidism who visited our clinics. The patients had to be 18 years or older and have been on a stable levothyroxine regimen for at least 6 months. Patients with a gastrointestinal tract disorder, those with thyroid carcinoma, and those who were pregnant were excluded from the study. Also excluded were patients who were taking medication known to interfere with the uptake of levothyroxine.^{4,7-10} The medical ethics committee of the Maastricht Hospital Rotterdam in the Netherlands approved the study protocol, and written informed consent was obtained from each patient.

RANDOMIZATION AND TREATMENT

After informed consent had been obtained, patients were randomized to start the study period with 1 capsule of levothyroxine in the morning (and 1 capsule of placebo at bedtime) or with 1 capsule of levothyroxine at bedtime (and 1 capsule

of placebo in the morning). After 3 months, patients were switched from levothyroxine in the morning to placebo and vice versa for another 3 months. Double-blind study medication was provided by the hospital pharmacy, which performed the randomization. Commercial levothyroxine sodium tablets (Thyrax Duotab, 0.100 mg; Organon, Oss, the Netherlands) were used and were reformulated as capsules with lactose monohydrate as the single excipient (in compliance with Good Manufacturing Practice guidelines, annex 13, manufacture of investigational medicinal products). Every patient received study capsules containing a similar dose of levothyroxine as before entry into the trial. Placebo and levothyroxine capsules were visually identical. Patients were instructed by a research nurse to take the morning capsule on an empty stomach half an hour before breakfast and the bedtime capsule at night just before going to bed.

DATA COLLECTION, FOLLOW-UP, AND COMPLIANCE

At baseline and every 6 weeks, patients were seen in our clinics by a research nurse. At these visits, blood samples were obtained to determine plasma thyrotropin, FT₄, T₃, creatinine, and lipid levels, and blood pressure, heart rate, and body weight were measured. The remaining capsules in the containers were counted to check for compliance. Quality-of-life questionnaires were completed by patients at baseline, at 3 months, and at the end of the study.

BLOOD SAMPLING

Blood samples were drawn on the morning of the planned visit to the research nurse. Capsules were not withheld on the day of blood sampling. Serum thyrotropin levels (reference range, 0.4-4.0 mIU/L) were measured by immunometric assay (Immulite 2000; DPC Nederland, Breda, the Netherlands), with a detection limit of 0.002 mIU/L. Levels of FT₄ (reference range, 10.0-24.0 pmol/L; equivalent to 0.78-1.86 ng/dL) and T₃ (reference range, 1.23-2.80 nmol/L; equivalent to approximately 80-182 ng/dL) were measured by competitive immunoassay (Immulite 2000). Creatinine and lipid levels were also measured (Dimension RxL; Dade Behring, Deerfield, Illinois).

Table 1. Baseline Characteristics of 90 Patients With Adequate Data for Analysis of the Primary Outcomes

Characteristic	Morning Levothyroxine Sodium Intake First (n=47)	Bedtime Levothyroxine Sodium Intake First (n=43)
Age, mean (SD), y	48 (11)	48 (13)
Male sex, No.	13	7
Body mass index, median (range) ^a	29.1 (20.0-40.1)	27.9 (19.8-41.0)
Etiology of hypothyroidism, No.		
Hashimoto disease	26	26
Sodium iodide I 131	17	17
Thyroidectomy	3	0
Neck radiation therapy	1	0
Duration of hypothyroidism, median (range), y	3.0 (0.5-25.0)	2.0 (0.5-21.0)
Levothyroxine dosage, median (range), µg	125 (50-200)	100 (50-250)
Thyrotropin level, mean (SD), mIU/L	1.5 (1.7)	3.3 (3.0)
Free thyroxine level, mean (SD), ng/dL	1.58 (0.26)	1.50 (0.27)
Triiodothyronine level, mean (SD), ng/dL	132.9 (30.7)	122.0 (38.1)
Patients who used other medications, No.	26	25

SI conversion factors: To convert thyrotropin level to micrograms per liter, multiply by 1.0; free thyroxine level to picomoles per liter, multiply by 12.871; total triiodothyronine level to nanomoles per liter, multiply by 0.0154.

^aCalculated as weight in kilograms divided by height in meters squared.

QUALITY OF LIFE AND PATIENT PREFERENCE

Three QOL questionnaires (36-Item Short Form Health Survey, Hospital Anxiety and Depression Scale, and 20-Item Multidimensional Fatigue Inventory) and a specific questionnaire about symptoms of hypothyroidism and hyperthyroidism were completed by patients at baseline, at 3 months, and at the end of the study. Patients completed the questionnaires under the supervision of a research nurse. The 36-Item Short Form Health Survey is a general QOL questionnaire that comprises 8 scales.¹⁸ The Hospital Anxiety and Depression Scale consists of 14 items pertaining to anxiety and depression.¹⁹ The 20-Item Multidimensional Fatigue Inventory measures 5 different dimensions of fatigue.²⁰ The specific questionnaire for thyroid symptoms assesses 14 symptoms of hypothyroidism and 6 symptoms of hyperthyroidism.²¹ At the end of the trial before the randomization code was broken, patients were asked during which period of the trial they had felt better. After the trial ended, patients were free to choose at what time of day they preferred to continue taking levothyroxine, in the morning or at bedtime. One year after the trial, we asked every patient at what time he or she was taking the levothyroxine tablet.

STATISTICAL ANALYSIS

The primary end point was a change in thyroid hormone variables (thyrotropin, FT₄, and total T₃ [TT₃] levels) between 12 weeks of morning levothyroxine intake and 12 weeks of bedtime levothyroxine intake. Secondary end points were changes in QOL (measured by 3 questionnaires), thyroid symptom score, body mass index, heart rate, and serum lipid and creatinine levels.

The direct treatment effect among all variables was measured by performing an independent-samples *t* test between the differences of week 12 and week 24 in the first group (started with morning levothyroxine) and the second group (started with bedtime levothyroxine).²² The presence of a carryover effect from one period to the other was measured by performing an independent-samples *t* test on the sum of the variables at 12 and 24 weeks in each patient. All *P* values were 2-sided and were not adjusted for multiple testing. All calculations were performed using commercially available statistical software (SPSS 17.0 for Windows; SPSS Inc, Chicago, Illinois).

To calculate the sample size, we assumed that a difference in thyrotropin level of 1.0 mIU/L between morning and bed-

time ingestion of levothyroxine would be clinically relevant. From previous results in a pilot study, we calculated that the standard deviation of the difference between morning and bedtime administration would be between 2.5 and 3.0 mIU/L. Based on these calculations, a sample size of 75 patients would give at least 80% power to detect a significant difference of 1 mIU/L between morning and bedtime administration.

RESULTS

STUDY PARTICIPANTS AND TREATMENT

Between April 1, 2007, and November 30, 2008, a total of 141 consecutive patients with primary hypothyroidism were assessed for study eligibility. Ultimately, 105 patients met the inclusion criteria and gave written informed consent. Reasons for exclusion were current use of interfering medication (n=11), history of thyroid carcinoma (n=3), unusual dosage of levothyroxine (n=6), treatment for breast cancer (n=1), and Addison disease (n=1). Fifteen randomized patients withdrew their consent shortly after enrollment in the trial and had baseline data only. The baseline characteristics of these patients did not differ from those of patients who completed the trial. Data for the entire 24 weeks were available for 90 patients (86%) who enrolled in the trial, 47 of whom started with levothyroxine intake in the morning and placebo at bedtime and 43 of whom started with levothyroxine intake at bedtime and placebo in the morning (**Figure 1**).

Baseline characteristics of the 2 groups are given in **Table 1**. There were differences between the 2 groups in the proportions of male patients, levothyroxine dosages, and thyrotropin levels. On average, patients missed a mean (SD) of 1.3 (6.0) capsules in the morning and 1.9 (10.1) capsules in the evening during 24 weeks of the trial (*P*=.54). Because there were no severe symptoms related to hypothyroidism or hyperthyroidism, no patient required a change in levothyroxine dosage during the trial.

Table 2. Laboratory Results and Measurements After 12 and 24 Weeks of Morning vs Bedtime Levothyroxine Sodium Intake in the 2 Randomized Study Groups

Variable	Mean (SD)					
	Morning Levothyroxine Sodium Intake First (n=47)			Bedtime Levothyroxine Sodium Intake First (n=43)		
	Baseline	12 wk	24 wk	Baseline	12 wk	24 wk
Thyrotropin level, mIU/L	1.52 (1.71)	2.66 (2.53)	1.74 (2.43)	3.31 (3.01)	2.36 (2.55)	3.86 (4.02)
Free thyroxine level, ng/dL	1.58 (0.26)	1.48 (0.24)	1.59 (0.33)	1.50 (0.27)	1.54 (0.28)	1.51 (0.20)
Total triiodothyronine level, ng/dL	132.9 (30.7)	121.2 (28.1)	127.0 (31.6)	122.0 (38.1)	128.4 (30.6)	121.9 (36.3)
Creatinine level, mg/dL	0.76 (0.17)	0.77 (0.21)	0.74 (0.16)	0.75 (0.28)	0.74 (0.26)	0.74 (0.29)
Total cholesterol level, mg/dL	194.3 (38.5)	197.1 (38.1)	191.3 (38.3)	201.2 (44.7)	198.9 (46.6)	199.0 (43.2)
Body mass index ^a	29.5 (5.4)	29.7 (5.6)	29.7 (5.6)	28.7 (4.6)	28.8 (4.6)	29.1 (4.8)
Heart rate, beats/min	75.0 (11.5)	79.0 (12.3)	79.0 (13.0)	77.0 (11.6)	78.0 (11.7)	77.0 (11.0)

Variable	Difference		Direct Treatment Effect (95% Confidence Interval)	P Value
	Morning Levothyroxine Sodium Intake First	Bedtime Levothyroxine Sodium Intake First		
Thyrotropin level, mIU/L	-0.92 (2.08)	1.57 (3.87)	1.25 (0.60 to 1.89)	<.001
Free thyroxine level, ng/dL	0.11 (0.27)	-0.04 (0.25)	-0.07 (-0.13 to -0.02)	.01
Total triiodothyronine level, ng/dL	5.80 (26.20)	-7.13 (26.30)	-6.46 (-12.10 to -0.90)	.02
Creatinine level, mg/dL	-0.03 (0.10)	0.00 (0.10)	0.020 (-0.001 to 0.037)	.13
Total cholesterol level, mg/dL	-5.75 (26.70)	0.57 (19.70)	3.16 (-1.90 to 8.20)	.22
Body mass index ^a	0.01 (0.80)	0.28 (0.60)	0.13 (-0.02 to 0.29)	.09
Heart rate, beats/min	0.93 (12.70)	-1.07 (8.90)	-1.00 (-3.40 to 1.40)	.40

SI conversion factors: To convert thyrotropin level to micrograms per liter, multiply by 1.0; free thyroxine level to picomoles per liter, multiply by 12.871; total triiodothyronine level to nanomoles per liter, multiply by 0.0154; creatinine level to micromoles per liter, multiply by 88.4; cholesterol level to millimoles per liter, multiply by 0.0259.

^aCalculated as weight in kilograms divided by height in meters squared.

PRIMARY OUTCOMES

Results of the primary outcomes are summarized in **Table 2** and in **Figure 2**. Among the group that received morning levothyroxine first, the mean (SD) thyrotropin level decreased from 2.66 (2.53) mIU/L at 12 weeks to 1.74 (2.43) mIU/L at 24 weeks. In contrast, among the group that received bedtime levothyroxine first, the mean (SD) thyrotropin level increased from 2.36 (2.55) mIU/L at 12 weeks to 3.86 (4.02) mIU/L at 24 weeks. When overall changes were compared between the 2 groups, bedtime levothyroxine intake was found to have a direct treatment effect, with a decrease in thyrotropin level of 1.25 mIU/L (95% confidence interval [CI], 0.60-1.89 mIU/L; $P < .001$) relative to morning levothyroxine intake.

The mean (SD) FT₄ level in the group that received morning levothyroxine first increased from 1.48 (0.24) ng/dL at 12 weeks to 1.59 (0.33) ng/dL at 24 weeks. In the group that received bedtime levothyroxine first, the mean (SD) FT₄ level decreased from 1.54 (0.28) ng/dL at 12 weeks to 1.51 (0.20) ng/dL at 24 weeks. Therefore, bedtime levothyroxine intake resulted in a direct treatment effect, with an increase in FT₄ level of 0.07 ng/dL (95% CI, 0.02-0.13; $P = .01$) relative to morning levothyroxine intake.

Changes in TT₃ levels were similar to changes in FT₄ levels. In the group that received morning levothyroxine first, the mean (SD) TT₃ level increased from 121.2 (28.1) ng/dL to 127.0 (31.6) ng/dL. In the group that re-

ceived bedtime levothyroxine first, the mean (SD) TT₃ level decreased from 128.4 (30.6) ng/dL to 121.9 (36.3) ng/dL. In this case, the direct treatment effect of bedtime levothyroxine was an increase in TT₃ level of 6.5 ng/dL (95% CI, 9.0-12.10 ng/dL; $P = .02$). No first-order carryover effect was found for thyrotropin, FT₄, or TT₃ levels.

SECONDARY OUTCOMES

There were no differences between the 2 study groups in serum creatinine or lipid levels, blood pressure, body mass index, or heart rate. These results are summarized in **Table 2**.

The 36-Item Short Form Health Survey, Hospital Anxiety and Depression Scale, and 20-Item Multidimensional Fatigue Inventory showed no differences in subscale or total scores between the periods of morning vs bedtime intake of levothyroxine (**Table 3**). Hypothyroidism symptoms were unchanged between the 2 periods, despite improved thyroid hormone profiles, nor was there a difference in hyperthyroidism symptoms.

PATIENT PREFERENCE

When asked at the end of the trial (before the randomization code was broken), 34 of 90 patients said that they felt better during the period of morning intake of levothyroxine, 31 patients preferred the period of bedtime intake, and 25 patients indicated no preference. At 1 year




Figure 2. Thyroid hormone levels after 6 and 12 weeks of morning or bedtime intake of levothyroxine sodium. To convert thyrotropin level to micrograms per liter, multiply by 1.0; free thyroxine level to picomoles per liter, multiply by 12.871; and total triiodothyronine level to nanomoles per liter, multiply by 0.0154.

after completion of the trial, more than half of the patients still preferred bedtime intake of levothyroxine.

COMMENT

We performed this large, randomized, double-blind crossover trial among 90 patients to address whether levothyroxine taken at bedtime instead of in the morning improves thyroid hormone levels. The primary outcomes show a decrease in thyrotropin level of 1.25 mIU/L and an increase in FT₄ and TT₃ levels when levothyroxine is taken at bedtime. Despite the change in thyroid hormone levels, the patient QOL did not differ. Bedtime levothyroxine intake could be more convenient for patients, as they do not have to postpone breakfast. After our study was completed, more than half of the patients decided to continue with bedtime intake of levothyroxine.

How can the bioavailability effects of levothyroxine be explained? An interval of 30 minutes between taking levothyroxine and eating breakfast may be too short to prevent interference with gastrointestinal absorption of

levothyroxine. Moreover, many patients drink coffee in the morning, often instead of eating breakfast,⁶ or may take other medications that interfere with levothyroxine absorption. In contrast, most patients in our study stated that they had eaten no food or snacks for several hours before bedtime, this being their usual routine. Bowel motility is slower at night, resulting in more prolonged exposure of levothyroxine to the intestinal wall and, consequently, in better bioavailability.²³ Furthermore, basal gastric acid secretion is highest in the late evening and is lowest in the morning.²⁴ An acidic environment promotes the absorption of levothyroxine.²⁵ These circadian differences in gastrointestinal function could be a pathophysiological explanation for our findings.

Thyroid hormone level changes did not translate into QOL changes. There are various explanations for this observation. Patients with hypothyroidism taking adequate doses of levothyroxine (ie, those whose thyrotropin level is in the reference range) can still have significant impairment in psychological well-being and cognitive function compared with control subjects.^{26,27} This could be related to their knowing that they have a chronic illness or are overweight. Weight gain and inability to lose weight are known to occur in patients with treated hypothyroidism and hyperthyroidism.^{28,29} In our study, body mass index was high in both study groups. A trial investigating T₃ supplementation showed that improved QOL was limited to a subgroup of patients with suppressed thyrotropin levels who had lost weight.³⁰ Based on the results of population studies,^{2,28} it has been suggested that the treatment goal in patients with hypothyroidism should be a thyrotropin level of 1.0 mIU/L or lower. In contrast, plasma thyroid hormone levels may not be representative of thyroid hormone levels at the tissue level (eg, in the brain); therefore, they would be unrelated to QOL.^{31,32} Finally, newly discovered thyroid hormone metabolites such as thyronamine that are not replaced by levothyroxine could influence QOL³³; furthermore, the presence of an autoimmune disorder (eg, Hashimoto disease) may have an effect on the brain and on QOL independent of thyroid hormone supplementation.³⁴

Primary outcomes of this study are consistent with results of an earlier pilot study.¹¹ Two other studies on the timing of levothyroxine intake have been published. In a retrospective medical record review of 15 nursing home residents, Elliott³⁵ observed a nonsignificant decrease in thyrotropin levels when levothyroxine intake was switched from after breakfast to midnight. The findings in that nonrandomized trial confirm the results of our study. A 3-period crossover design study³⁶ showed higher thyrotropin levels when levothyroxine was taken at bedtime instead of before breakfast, but there was no change in FT₄ or TT₃ levels, as in our study. The exclusion criteria for that study were extensive, and only 19% of eligible patients were agreeable to participation. The study also included patients with thyroid cancer, whose thyrotropin levels were maintained at lower levels than those of the rest of the population. Therefore, we believe that the findings in that study extend the generalizability of our study results to the treatment of primary hypothyroidism. Lower thyrotropin levels associated with levothyroxine intake before breakfast vs at bedtime intake in

Table 3. Quality of Life and Symptoms After 12 and 24 Weeks of Morning vs Bedtime Levothyroxine Sodium Intake in the 2 Randomized Study Groups

Variable	Score, Mean (SD)					
	Morning Levothyroxine Sodium Intake First			Bedtime Levothyroxine Sodium Intake First		
	Baseline	12 wk	24 wk	Baseline	12 wk	24 wk
36-Item Short Form Health Survey						
Physical functioning	62.7 (20.2)	64.5 (19.6)	62.7 (20.9)	65.2 (17.9)	67.4 (16.4)	66.5 (16.4)
Social functioning	72.3 (23.6)	71.5 (26.8)	70.9 (23.0)	65.8 (27.5)	73.0 (20.6)	71.2 (24.2)
Role limitations due to physical problems	55.9 (42.4)	63.0 (40.7)	59.2 (41.3)	65.6 (39.9)	57.9 (42.0)	67.9 (39.5)
Role limitations due to emotional problems	72.3 (41.3)	73.9 (37.1)	69.6 (39.0)	79.4 (35.3)	71.4 (36.5)	69.8 (40.4)
Mental health	70.3 (17.8)	69.6 (18.6)	68.3 (17.8)	65.2 (20.1)	63.7 (21.8)	66.0 (21.7)
Vitality	50.0 (23.7)	55.1 (21.2)	52.0 (22.9)	51.1 (20.0)	52.2 (20.2)	52.6 (20.4)
Pain	73.3 (26.2)	73.8 (25.3)	72.8 (23.5)	75.6 (26.7)	75.6 (28.7)	76.7 (28.0)
General health	53.8 (22.4)	56.5 (22.7)	56.6 (21.6)	56.7 (21.9)	59.3 (23.2)	58.8 (22.7)
Hospital Anxiety and Depression Scale						
Anxiety	6.3 (4.5)	6.5 (4.5)	5.9 (4.2)	7.0 (4.2)	7.1 (5.0)	7.2 (4.3)
Depression	5.0 (3.8)	4.8 (4.1)	4.4 (3.8)	5.8 (4.0)	5.0 (4.5)	5.6 (5.0)
20-Item Multidimensional Fatigue Inventory						
General fatigue	12.7 (5.3)	11.9 (4.9)	12.2 (5.0)	12.4 (5.1)	12.3 (5.1)	12.4 (5.5)
Physical fatigue	12.5 (5.4)	11.1 (4.9)	11.7 (4.8)	12.8 (4.5)	11.8 (4.7)	11.3 (4.6)
Reduced activity	10.8 (4.3)	10.5 (4.1)	10.7 (4.4)	11.1 (4.5)	11.2 (4.5)	11.2 (4.1)
Reduced motivation	9.6 (4.3)	9.7 (4.7)	9.9 (4.5)	10.8 (4.0)	10.7 (4.4)	10.7 (4.1)
Mental fatigue	9.8 (5.0)	10.4 (5.1)	10.0 (4.8)	11.0 (5.4)	11.0 (5.1)	10.4 (4.2)
Symptoms						
Hypothyroidism	29.8 (8.6)	27.2 (7.7)	28.7 (8.3)	31.5 (9.4)	29.2 (8.5)	29.6 (8.8)
Hyperthyroidism	11.5 (3.7)	11.0 (3.3)	10.8 (3.5)	12.5 (3.9)	12.1 (3.8)	12.0 (4.3)
Variable	Difference			Direct Treatment Effect (95% Confidence Interval)	P Value	
	Morning Levothyroxine Sodium Intake First	Bedtime Levothyroxine Sodium Intake First				
36-Item Short Form Health Survey						
Physical functioning	-2.56 (13.43)	-0.83 (10.93)		0.86 (-1.26 to 3.50)	.52	
Social functioning	-2.22 (23.43)	-1.74 (20.52)		0.24 (-4.44 to 4.92)	.92	
Role limitations due to physical problems	-4.44 (38.54)	8.75 (35.15)		6.60 (-1.40 to 14.60)	.10	
Role limitations due to emotional problems	-3.70 (43.36)	-0.79 (39.98)		1.46 (-7.46 to 10.37)	.75	
Mental health	-1.28 (12.82)	2.67 (13.73)		1.97 (-0.83 to 4.77)	.16	
Vitality	-3.09 (20.07)	0.35 (15.75)		1.72 (-2.09 to 5.52)	.37	
Pain	-1.00 (19.09)	1.09 (20.19)		1.05 (-3.07 to 5.16)	.62	
General health	-1.56 (15.48)	-0.73 (13.99)		0.41 (-2.77 to 3.59)	.80	
Hospital Anxiety and Depression Scale						
Anxiety	-0.60 (2.53)	0.09 (2.93)		0.34 (-0.23 to 0.92)	.23	
Depression	-0.45 (2.66)	0.55 (3.03)		0.50 (-0.10 to 1.10)	.10	
20-Item Multidimensional Fatigue Inventory						
General fatigue	0.30 (4.13)	0.17 (3.77)		-0.07 (-0.91 to 0.77)	.88	
Physical fatigue	0.55 (3.89)	-0.51 (3.82)		-0.53 (-1.34 to 0.28)	.19	
Reduced activity	0.23 (3.44)	-0.10 (3.94)		-0.16 (-0.94 to 0.62)	.67	
Reduced motivation	0.15 (3.75)	-0.05 (4.34)		-0.10 (-0.95 to 0.75)	.82	
Mental fatigue	-0.34 (4.14)	-0.56 (3.91)		-0.11 (-0.96 to 0.74)	.80	
Symptoms						
Hypothyroidism	1.45 (7.14)	0.42 (5.11)		-0.51 (-1.83 to 0.80)	.44	
Hyperthyroidism	-0.15 (3.16)	-0.12 (2.80)		0.02 (-0.61 to 0.65)	.96	

that study could be explained by the longer interval between levothyroxine intake and breakfast (60 minutes vs 30 minutes in our study). Also, most patients in our study stated that they had nothing to eat (or only a small snack) for several hours before bedtime, which differs across cultures. In all studies performed on the timing of levothyroxine ingestion, intake on an empty stomach seems to result in maximal absorption of levothyroxine. Our study shows that if this fasting regimen can be achieved at bedtime, then resulting thyroid hormone lev-

els are better than those associated with levothyroxine intake 30 minutes before breakfast.

The crossover design of our study has the advantage that each patient served as his or her own control. Therefore, a statistical difference in thyrotropin values at baseline will not influence primary and secondary outcomes of the study. The study design has potential limitations, including order and sequence effects. We found no first-order carryover effect between the 2 periods, but we looked at no other order or sequence effects. It should

also be noted that this was a single-site study in the Netherlands, where eating habits might be different from those in other countries or cultures.

Based on the results of our study, clinicians should inform patients with hypothyroidism that levothyroxine intake at bedtime is a good alternative to levothyroxine intake in the morning, provided that levothyroxine is taken on an empty stomach. For patients who do not attain normal thyrotropin or FT₄ levels with morning levothyroxine intake, a switch to bedtime is recommended. Recommendations on timing of levothyroxine intake and on uptake interference by food are found in few guidelines about the management of hypothyroidism.^{37,38} Drug information resources and guidelines require revision in this respect.

In conclusion, bedtime intake of levothyroxine in our study significantly improved thyroid hormone levels. This may be explained by better gastrointestinal bioavailability at night or by less uptake interference by food or medications. As shown in this study, bedtime administration is more convenient for many patients. Clinicians should inform their patients about the possibility of taking levothyroxine at bedtime. A prolonged period of bedtime levothyroxine therapy may be required for a change in QOL to occur.

Accepted for Publication: June 1, 2010.

Correspondence: Nienke Bolk, MD, Department of Internal Medicine, Maastad Hospital Rotterdam, 315 Groene Hilledijk, 3075 EA Rotterdam, the Netherlands (nienkebolk@hotmail.com).

Authors Contributions: Dr Bolk had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Bolk, Visser, and Berghout. Acquisition of data: Bolk, Jongste, and Berghout. Analysis and interpretation of data: Bolk, Visser, Nijman, Tijssen, and Berghout. Drafting of the manuscript: Bolk, Visser, Nijman, Jongste, Tijssen, and Berghout. Critical revision of the manuscript for important intellectual content: Visser, Tijssen, and Berghout. Statistical analysis: Nijman and Tijssen. Administrative, technical or material support: Nijman and Jongste. Study supervision: Berghout.

Financial Disclosure: None reported.

Previous Presentation: These study data were presented in preliminary form at the 91st Annual Meeting of The Endocrine Society; June 11, 2009; Washington, DC.

Additional Contributions: Liesbeth Ruygrok, PhD, oversaw preparation of the levothyroxine and placebo capsules and randomization of the patients. Maastad Hospital Rotterdam laboratory technicians processed the blood samples, and employees of the Department of Internal Medicine assisted with patient assessment. We thank the patients who participated in this study for their cooperation.

REFERENCES

1. Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham Survey. *Clin Endocrinol (Oxf)*. 1977;7(6):481-493.
2. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T₄, and thyroid an-

- tibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab*. 2002;87(2):489-499.
3. Wenzel KW, Kirschsieper HE. Aspects of the absorption of oral L-thyroxine in normal man. *Metabolism*. 1977;26(1):1-8.
4. Sherman SI, Tielens ET, Ladenson PW. Sucralfate causes malabsorption of L-thyroxine. *Am J Med*. 1994;96(6):531-535.
5. Liel Y, Harman-Boehm I, Shany S. Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients. *J Clin Endocrinol Metab*. 1996;81(2):857-859.
6. Benvenga S, Bartolone L, Pappalardo MA, et al. Altered intestinal absorption of L-thyroxine caused by coffee. *Thyroid*. 2008;18(3):293-301.
7. Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. *JAMA*. 2000;283(21):2822-2825.
8. Sachmechi I, Reich DM, Aninyei M, Wibowo F, Gupta G, Kim PJ. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. *Endocr Pract*. 2007;13(4):345-349.
9. Campbell NR, Hasinoff BB, Stalts H, Rao B, Wong NC. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. *Ann Intern Med*. 1992;117(12):1010-1013.
10. Siraj ES, Gupta MK, Reddy SS. Raloxifene causing malabsorption of levothyroxine. *Arch Intern Med*. 2003;163(11):1367-1370.
11. Bolk N, Visser TJ, Kalsbeek A, van Domburg RT, Berghout A. Effects of evening vs morning thyroxine ingestion on serum thyroid hormone profiles in hypothyroid patients. *Clin Endocrinol (Oxf)*. 2007;66(1):43-48.
12. Esposito S, Prange AJ Jr, Golden RN. The thyroid axis and mood disorders: overview and future prospects. *Psychopharmacol Bull*. 1997;33(2):205-217.
13. Duyff RF, Van den Bosch J, Laman DM, van Loon BJ, Linssen WH. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. *J Neurol Neurosurg Psychiatry*. 2000;68(6):750-755.
14. Tielens ET, Pillay M, Storm C, Berghout A. Changes in cardiac function at rest before and after treatment in primary hypothyroidism. *Am J Cardiol*. 2000;85(3):376-380.
15. den Hollander JG, Wulkan RW, Mantel MJ, Berghout A. Correlation between severity of thyroid dysfunction and renal function. *Clin Endocrinol (Oxf)*. 2005;62(4):423-427.
16. Friis T, Pedersen LR. Serum lipids in hyper- and hypothyroidism before and after treatment. *Clin Chim Acta*. 1987;162(2):155-163.
17. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. *J Clin Endocrinol Metab*. 2003;88(6):2438-2444.
18. Van der Zee KI, Sanderman S. *Het Meten van de Algemene Gezondheidstoestand met de RAND-36: een Handleiding [Measurement of General Health With the RAND-36: A Manual]*. Groningen, the Netherlands: Noorderlijk Centrum voor Gezondheidsvraagstukken, Rijks Universiteit Groningen; 1993.
19. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand*. 1983;67(6):361-370.
20. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI): psychometric qualities of an instrument to assess fatigue. *J Psychosom Res*. 1995;39(3):315-325.
21. Lazarus JH, Hall R, Othman S, et al. The clinical spectrum of postpartum thyroid disease. *QJM*. 1996;89(6):429-435.
22. Kenward MG, Rao CR, Rao DC, eds. Design and analysis of cross-over trials. In: *Handbook of Statistics*. 2nd ed. Amsterdam, the Netherlands: Elsevier Science; 2008:464-490.
23. Wilson P, Perdakis G, Hinder RA, Redmond EJ, Anselmino M, Quigley EM. Prolonged ambulatory antroduodenal manometry in humans. *Am J Gastroenterol*. 1994;89(9):1489-1495.
24. Moore JG, Englert E Jr. Circadian rhythm of gastric acid secretion in man. *Nature*. 1970;226(5252):1261-1262.
25. Centanni M, Gargano L, Canetti G, et al. Thyroxine in goiter, *Helicobacter pylori* infection, and chronic gastritis. *N Engl J Med*. 2006;354(17):1787-1795.
26. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on "adequate" doses of L-thyroxine: results of a large, controlled community-based questionnaire study. *Clin Endocrinol (Oxf)*. 2002;57(5):577-585.
27. Wekking EM, Appelhof BC, Fliers E, et al. Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. *Eur J Endocrinol*. 2005;153(6):747-753.
28. Hamilton TE, Davis S, Onstad L, Kopecky KJ. Thyrotropin levels in a population with no clinical, autoantibody, or ultrasonographic evidence of thyroid disease: implications for the diagnosis of subclinical hypothyroidism. *J Clin Endocrinol Metab*. 2008;93(4):1224-1230.
29. Hoogwerf BJ, Nuttall FQ. Long-term weight regulation in treated hyperthyroid and hypothyroid subjects. *Am J Med*. 1984;76(6):963-970.

30. Appelhof BC, Fliers E, Wekking EM, et al. Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial. *J Clin Endocrinol Metab.* 2005;90(5):2666-2674.
31. Escobar-Morreale HF, Obregón MJ, Escobar del Rey F, Morreale de Escobar G. Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats. *J Clin Invest.* 1995;96(6):2828-2838.
32. Roos A, Linn-Rasker SP, van Domburg RT, Tijssen JP, Berghout A. The starting dose of levothyroxine in primary hypothyroidism treatment: a prospective, randomized, double-blind trial. *Arch Intern Med.* 2005;165(15):1714-1720.
33. Scanlan TS. Minireview: 3-iodothyronamine (T1AM): a new player on the thyroid endocrine team? *Endocrinology.* 2009;150(3):1108-1111.
34. Vonk R, van der Schot AC, Kahn RS, Nolen WA, Drexhage HA. Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder? *Biol Psychiatry.* 2007;62(2):135-140.
35. Elliott DP. Effect of levothyroxine administration time on serum TSH in elderly patients. *Ann Pharmacother.* 2001;35(5):529-532.
36. Bach-Huyhng TG, Nayak B, Loh J, Soldin S, Jonklaas J. Timing of levothyroxine administration affects serum thyrotropin concentration. *J Clin Endocrinol Metab.* 2009;94(10):3905-3912.
37. Woeber KA. Update on the management of hyperthyroidism and hypothyroidism. *Arch Intern Med.* 2000;160(8):1067-1071.
38. Singer PA, Cooper DS, Levy EG, et al; Standards of Care Committee, American Thyroid Association. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. *JAMA.* 1995;273(10):808-812.

Call for Photographs

The *Archives* is seeking photographs to be included as fillers in our journal. We believe that our readers may be an excellent source of interesting and thoughtful photographs. If you would like us to consider your photography for publication, we invite you to submit your photograph to our Web-based submission site under the category Images From Our Readers at <http://manuscripts.archinternmed.com>. Please upload photograph submissions in .jpg or .tif format. Hard copy photographs are not acceptable. For more information please e-mail archinternmed@jama-archives.org.